ArticleCancer medicine2026
Improved Locoregional Recurrence-Free Survival With Carbon Ion Versus Photon Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionCarbon ion radiotherapy (CIRT) delivers high linear energy transfer radiation with superior dose conformity compared with photon radiotherapy (PRT). However, whether these physical advantages translate into clinical benefit for locally advanced non-small cell lung cancer (LA-NSCLC) in the era of modern systemic therapy remains unclear.
methodsWe performed a retrospective, propensity score-matched cohort study of patients with Stage III LA-NSCLC treated with definitive CIRT or PRT as part of multimodality therapy between January 2016 and December 2023. The primary endpoint was locoregional recurrence-free survival (LRFS). Secondary endpoints included progression-free survival (PFS), overall survival (OS), distant metastasis-free survival (DMFS), and acute grade ≥ 2 radiation-related adverse events (AEs).
resultsA total of 292 patients were matched (146 per group). With a median follow-up of 32.5 months, CIRT group demonstrated significantly longer median LRFS (57.7 vs. 25.0 months; HR, 0.59; 95% CI, 0.39-0.88; p = 0.01) and median PFS (17.7 vs. 16.7 months; HR, 0.70; 95% CI, 0.53-0.94; p = 0.02) compared with PRT group, whereas OS and DMFS were similar between groups. CIRT group also had fewer acute grade ≥ 2 radiation-related AEs.
conclusionsCIRT demonstrated improved locoregional control and fewer acute toxicities compared with PRT in LA-NSCLC in this retrospective matched cohort. Prospective randomized trials are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.